Aims/hypothesis. To investigate the incidence of foetal macrosomia (i.e. birth weight >90th percentile) in a nonselected nationwide cohort of women with Type I (insulin-dependent) diabetes mellitus in The Netherlands and to identify risk indicators predictive for macrosomia. Methods. We conducted a prospective nationwide cohort based survey regarding the outcome of Type I diabetic pregnancy in The Netherlands. Data of 289 women who gave birth to a live singleton infant without major congenital malformations at more than or equal to 28 weeks of gestation are shown.
rosomia is related to an increased risk for "unexplained" death in utero and shoulder dystocia during labour, the latter being related to asphyxia, clavicle fracture and/or Erbs palsy [1, 2, 3] . During the neonatal period macrosomic infants are at increased risk for hypoglycaemia, infant respiratory distress syndrome (IRDS), hyperbilirubinaemia and hypertrophic cardiomyopathy [4, 5, 6] . A number of long-term population studies have shown that macrosomic newborns of women with diabetes have a higher risk to develop obesity and Type II (non-insulin-dependent) diabetes mellitus at a young age [7, 8, 9] .
Foetal growth depends on foetal, placental and maternal factors. Determinants affecting foetal growth are genetic factors, fetal hormones (insulin, insulinPrevention of foetal macrosomia in pregnancies with Type I (insulin-dependent) diabetes mellitus would reduce serious perinatal morbidity and mortality. Maclike growth factors), uterine constraints (placental functioning, substrate flow) and maternal factors (parity, smoking, obesity, height, weight gain in pregnancy, prolonged pregnancy) [10] . Maternal diabetes is associated with abnormal -excessive -fetal growth. Hyperglycaemia is considered a determinant of excessive foetal growth, although the relationship between glycaemic control during pregnancy and the occurrence of macrosomia is lower than might be expected. Differences in HbA 1c explained only 6 to 23% of the variance in birth weight [5, 11, 12] , whereas 1 h postprandial blood glucose values predicted 28.5% of the macrosomic infants born to diabetic mothers [13] . This relatively weak relationship could be due to the use of inadequate markers of (overall) glycaemic control or due to other yet unknown factors.
However, despite improved glycaemic control over the past decade, the incidence of macrosomia is still very high (27-43%) and does not seem to decline [1, 4, 5, 14, 15, 16, 17] . When trying to reduce macrosomia in Type I diabetic pregnancies, it would be useful to know the characteristics of women with the highest risk for having a macrosomic infant.
We assessed the incidence of macrosomia in a nonselected prospective nationwide cohort based study of pregnant Type I diabetic women in The Netherlands and investigated the clinical characteristics of the women who gave birth to a macrosomic infant.
Subjects and methods
All gynaecologists, internists and diabetes nurse educators in The Netherlands were asked to include all Type I diabetic women presenting themselves for antenatal care, between 1 st April 1999 and 1 st April 2000, in a cohort based survey regarding the outcome of Type I diabetic pregnancy in The Netherlands. Eligible pregnant women were asked to fill out sets of questionnaires at inclusion (at ~10 weeks gestation), at the end of the first trimester (at ~17 weeks) and during the third trimester (at ~34 weeks).
All 118 Dutch hospitals participated in the study and a total of 364 eligible women were reported to the study co-ordinator. In this paper data of the 289 women who gave birth to a live singleton infant without major congenital malformations at more than or equal to 28 weeks of gestation are shown.
The study had been approved by the Ethical Committee of University Medical Centre, Utrecht, The Netherlands. Participants gave written informed consent.
We recorded the following factors: of maternal severe hypoglycaemia (SH) during the first trimester and third trimester of pregnancy (second and third questionnaire). Severe hypoglycaemia (SH) was defined as all episodes for which external help had been required including hypoglycaemic coma [19, 20] . The proportion of women who were affected by at least one episode of SH during the first trimester and third trimester of pregnancy is reported. (v) Co-morbidity and pregnancy related morbidity. Pre-existing hypertension was defined as a diastolic blood pressure greater than or equal to 90 mm Hg in the first half of pregnancy. Pre-eclampsia was defined as a diastolic blood pressure greater than or equal to 90 mm Hg on two occasions at least 4 hours apart and proteinuria greater than or equal to 300 mg per 24 hours in the second half of pregnancy in a previously normotensive woman [21] . In patients with pre-existing hypertension, pre-eclampsia was diagnosed when a de novo proteinuria greater than or equal to 300 mg per 24 hours occurred in the second half of pregnancy. Demographics. Age, race and parity were not related to macrosomia. The proportion of non-smokers was higher among women with a macrosomic infant as compared to women with a non-macrosomic infant.
Diabetes and treatment. Virtually all women (98%)
were treated with intensive insulin treatment. Women with and without macrosomic infants were not significantly different with respect to duration of diabetes, long-term diabetic complications, total daily insulin dosage (U/kg) in the first trimester and in the third trimester of pregnancy, increase in insulin dosage during pregnancy and use of insulin lispro. However, more women with a macrosomic infant were treated with CSII (45% vs 31%; p=0.01).
Glycaemic control during pregnancy. Second and third trimester HbA 1c and mean HbA 1c during pregnancy were higher in the women with a macrosomic infant. Glycaemic control was excellent (i.e. within the non-diabetic range) in 40%, good in 44% and not optimal in 16% of the pregnancies. In 79% of the pregnancies with a macrosomic infant and in 89% of the pregnancies with a non-macrosomic infant glycaemic control was excellent or good (p=0.03). Mean HbA 1c early in pregnancy measured in a central laboratory, was higher in the women with a macrosomic infant (6.8±0.7% vs 6.5±0.7%; p=0.01).
Severe hypoglycaemia (SH) during pregnancy. Fewer women with a macrosomic infant reported one or more episodes of SH during the first trimester and third trimester of pregnancy compared to the women with a non-macrosomic infant. Mean HbA 1c during pregnancy was higher in women without any SH than in women with SH during pregnancy (i.e. during first and/or third trimester) (6.4±0.9% vs 6.0±0.7%; p=0.002).
Co-morbidity and pregnancy related morbidity. There was no difference in pre-existing hypertension and pre-eclampsia between both groups.
Weight and weight gain. Pre-pregnancy BMI and weight gain during pregnancy were not different between both groups. 
Multiple Logistic Regression Analysis of risk indica
, sex, parity and race. Severe macrosomia was defined as a birth weight greater than the 97.7th percentile.
Statistical analysis. Statistical analysis was carried out using the statistical package SPSS (SPSS Release 10.0, SPSS, Chicago, Ill., USA). Data are shown as means with standard deviations or as percentages. We compared characteristics of the women who delivered a macrosomic infant to characteristics of the women with a normal birth weight infant. Continuous data were compared using the unpaired Student's t test (two-tailed) and categorical data were compared using the chi square test. First, univariate analysis was due, in which odds ratios (OR) and 95% confidence intervals (CI) as well as p values were calculated for both dichotomous and continuous variables. Subsequently, multiple logistic regression analysis was used to construct a prediction model for macrosomia. Stepwise selection of variables was applied, with a p value of 0.15 as entry-criterion. The area under the receiver operating characteristic curve (ROC-curve), which can yield values from 0.5 (no predictive power) to 1 (perfect prediction), was computed to assess the predictive accuracy of the constructed logistic model.
Results
The mean (±SD) birth weight of the 289 infants was 3566±711 grams (g) at 37.3±1.9 weeks of gestation. Of these infants, 162 (56.1%) were macrosomic, including 88 (30.4%) severely, according to the official Dutch growth charts. These percentages were 48.8% and 26.6% respectively, according to the growth charts based on data collected in 1998 (Fig. 1) . Of the infants, 73 (25.3%) had a birth weight greater than 4000 g including 22 infants (7.6%) with a birth weight greater than 4500 g. The characteristics of the 289 women are shown in the first column of Table 1 . 
Discussion
This study shows that in a non-selected group of women with Type I diabetes mellitus, macrosomia occurred in more than half (56.1%) or almost half of them (48.8%), depending on the reference growth chart used. Since population birth weight has increased over the years, the use of an up-to-date chart is essential. The incidence reported in our study is in concordance with the incidences of (severe) macrosomia reported from other Northern European countries in the last decade. In Sweden (1991-1996) more than 33% of the infants from Type I diabetic mothers were severe macrosomic [1] , in Denmark (1993 Denmark ( -1999 27.6% of the infants were macrosomic (birth weight ≥ 4000 g) [16] and from Finland a marked increase in the number of macrosomic infants (to 34%) was reported [17] . In Type I diabetic pregnancy, foetal macrosomia is still a significant, and could even be a rising problem, despite modern therapy (i.e. intensive insulin treatment).
We found a high incidence of macrosomia despite overall good glycaemic control, as assessed by HbA 1c , in most of the women. Third trimester HbA 1c was an independent risk indicator for macrosomia, which is in agreement with other studies [4, 5] . A third trimester HbA 1c greater than 6.5% was associated with a twofold to threefold increase in macrosomia. However, although third trimester HbA 1c was the most powerful predictor of macrosomia that we detected, its predictive capacity was only weak (explained variance <5%). This implies that glycaemic control measured by conventional methods (i.e. HbA 1c ) does not explain the high incidence of macrosomia. Several phenomena could contribute to the explanation of this. Firstly, glucose variability and post-prandial hyperglycaemic episodes, which are not reflected in the HbA 1c -value, can be involved. This means that more detailed assessments of glycaemic control, such as continuous subcutaneous glucose measurement techniques, are needed to monitor women with Type I diabetes during pregnancy. The advent of continuous glucose monitoring has recently been applied in pregnant women with gestational diabetes [24] . This study showed that the continuous glucose monitoring system (CGMS) detects post-prandial glucose increases that were not detected by conventional intermittent self-monitoring of blood glucose (SMBG). Perhaps the statement "macrosomia despite normoglycaemia" should rather say "macrosomia because of undetected (post-prandial) hyperglycaemia" [25] . The application of the CGMS enables more tailored insulin therapy. Therefore, using CGMS might be helpful in optimising glycaemic control and in reducing the incidence of macrosomia in Type I diabetic pregnancy.
Secondly, observations in foetal sheep showed that continually high values of maternal glucose did not stimulate continuing foetal hyperinsulinism, but that "pulsatile" hyperglycaemia did [26] . So, intermittent hyperglycaemia (usually with normal HbA 1c ) could be more important than chronic hyperglycaemia (usually with higher HbA 1c ) in causing accelerated foetal growth [27] .
Thirdly, poor glycaemic control early in pregnancy has been associated with congenital malformations and early growth delay [28] . Nowadays, most of the diabetic women enter their pregnancy well-controlled, which was also the case in our cohort [29] . We could speculate that improved early glycaemic control favours placental development and subsequently foetal growth.
Several studies have reported an increased incidence of severe hypoglycaemia (SH) during pregnancy, with the highest rate in the first trimester [30, 31, 32] . The main reason for this high rate is striving for tight glycaemic control (i.e. HbA 1c ≤6.5%) [32] . In our study, absence of third trimester SH increased the risk of macrosomia. Other studies also have reported non-significant higher incidences of macrosomia in women not affected by SH during pregnancy (38% vs 20% and 48% vs 31%; both p>0.05) [30, 31] . Since the number of patients in those studies was much lower (≈85 women), the power to detect a statistically significant association between the occurrence of SH and a decreased macrosomia rate could have been too small. Mean HbA 1c during pregnancy (i.e. overall glycaemic control) was higher in women without any SH than in women with SH during pregnancy. This might explain the increased risk of macrosomia in these women. Animal studies have shown that experimentally induced chronic maternal hyperinsulinaemia and hypoglycaemia during pregnancy resulted in foetal hypoglycaemia, hypo-insulinaemia and intra-uterine growth retardation [33] .
Studies regarding the use of insulin lispro and infant birth weight in Type I diabetic pregnancies are scarce. A study observed a trend towards less macrosomia [34] , and another showed no significant difference in the prevalence of macrosomia [35] . In our study, 11% of the women were treated with insulin lispro. Surprisingly, the use of insulin lispro was associated with an increased risk of macrosomia. Possibly, the women who were treated with insulin were a selected group of women, i.e. especially those women with difficulties in optimising their glycaemic control. In these women first, second and third trimester HbA 1c , and mean HbA 1c during pregnancy were higher, but the differences were not statistically significant.
Weight gain during pregnancy and non-smoking were also independent risk indicators for macrosomia. This observation is in agreement with earlier findings in diabetic and non-diabetic populations [36, 37] .
The area under the curve of 0.71 for the prediction of macrosomia indicated that the capacity of the five indicators to predict macrosomia was very limited. So, we are not able to explain the extremely high incidence of macrosomia in our study with these variables.
In conclusion, despite apparent good glycaemic control during pregnancy, the incidence of foetal macrosomia in this non-selected prospective nationwide cohort of 289 Type I diabetic women was very high. A higher third trimester HbA 1c (>6.5%), absence of third trimester SH, the use of insulin lispro, weight gain during pregnancy and non-smoking were risk indicators predictive for the occurrence of macrosomia. Third trimester HbA 1c was the most powerful predictor, but its predictive capacity was weak. Thus, future research should focus on new, more detailed glucose monitoring techniques (such as CGMS) as well as alternative factors to reduce macrosomia. 
